Deaf girl is cured in world first gene therapy trial
Gene therapy restoring hearing to a child born profoundly deaf is prompting both excitement and careful scrutiny. Commenters unpack how the AAV-based treatment works, how it differs from CRISPR, and whether similar approaches could one day address conditions like color blindness, retinitis pigmentosa, or other genetic forms of deafness. Alongside technical optimism, many raise ethical and social questions around Deaf culture, eugenics, consent, cost, and who will actually get access to such transformative interventions.
Mechanism of the Therapy (Not CRISPR)
- Commenters clarify this is AAV-based gene therapy, not CRISPR.
- An adeno‑associated virus delivers otoferlin cDNA into inner‑ear hair cells.
- The DNA remains as an episome (circular extra-chromosomal DNA), not integrated into the genome, reducing risk of disrupting other genes.
- Hair cells do not turn over during life, so a “protein factory” in those cells could provide durable benefit.
Prospects for Other Conditions
- Strong interest in applying similar approaches to:
- Red‑green color blindness (fixing opsin genes in cones).
- Retinitis pigmentosa and other inherited retinal diseases.
- Other monogenic hearing losses (e.g., GJB2/connexin 26, STRC; specific pipelines cited).
- Some note regulatory bodies currently see gene therapy risk as too high for non‑severe conditions like color blindness.
Subjective Experience of Gaining a New Sense
- Curiosity about how it feels to gain hearing or new color perception later in life.
- Discussion of brain plasticity, “critical periods,” and mixed evidence: some abilities must be learned early, but adults can also adapt to major sensory changes.
- Personal anecdotes about regaining smell or improving vision illustrate both wonder and difficulty of adaptation.
Deaf Culture, Disability, and Ethics
- Several note parts of the Deaf community oppose cochlear implants and may resist gene therapy, seeing deafness as identity (“deaf gain”), not defect.
- Fears include cultural loss, pressure to “fit in” to hearing society, and echoes of eugenics.
- Others argue restoring a nonfunctional sense is clearly beneficial, likening deafness to lacking legs rather than being short.
- Broader debate over where to draw the line between therapy and enhancement, and who decides (individuals vs parents vs state).
Regulation, Safety, and DIY Bio
- Historical gene‑therapy setbacks (e.g., a high‑profile death) are cited as reasons for slow progress.
- Discussion of FDA’s role: protecting patients vs allowing high‑risk elective treatments; proposal of a “middle tier” approval.
- DIY gene editing and self‑experimentation are criticized as reckless; laypeople may be unable to grasp all risks.
Costs, Access, and Inequality
- Enthusiasm is tempered by concern that advanced therapies will be extremely expensive and mainly available to the privileged.
- Broader worries about U.S. healthcare costs, insurance gaps, and misaligned incentives in pharma and medical practice.
Personal Stories and Emotional Impact
- Deaf and hard‑of‑hearing commenters share experiences with cochlear implants, otosclerosis, and IVF with genetic screening.
- Some celebrate the news as evidence that medical science is one of the few consistent sources of hope amid wider societal problems.